Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Identifieur interne : 001956 ( Main/Corpus ); précédent : 001955; suivant : 001957Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
Auteurs : Dan M. Roden ; Robert A. Harrington ; Athena Poppas ; Andrea M. RussoSource :
- Heart rhythm [ 1556-3871 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Infective Agents (administration & dosage), Anti-Infective Agents (adverse effects), Azithromycin (administration & dosage), Azithromycin (adverse effects), Betacoronavirus (drug effects), COVID-19 (MeSH), Contraindications, Drug (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Drug Interactions (MeSH), Drug Monitoring (methods), Drug Therapy, Combination (adverse effects), Drug Therapy, Combination (methods), Electrocardiography (methods), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Long QT Syndrome (chemically induced), Long QT Syndrome (diagnosis), Long QT Syndrome (prevention & control), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Torsades de Pointes (chemically induced), Torsades de Pointes (diagnosis), Torsades de Pointes (prevention & control).
- MESH :
- chemical , administration & dosage : Anti-Infective Agents, Azithromycin, Hydroxychloroquine.
- chemical , adverse effects : Anti-Infective Agents, Azithromycin, Hydroxychloroquine.
- adverse effects : Drug Therapy, Combination.
- chemically induced : Long QT Syndrome, Torsades de Pointes.
- complications : Coronavirus Infections.
- diagnosis : Long QT Syndrome, Torsades de Pointes.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- methods : Drug Monitoring, Drug Therapy, Combination, Electrocardiography.
- prevention & control : Long QT Syndrome, Torsades de Pointes.
- COVID-19, Contraindications, Drug, Drug Interactions, Humans, Pandemics, SARS-CoV-2.
DOI: 10.1016/j.hrthm.2020.04.016
PubMed: 32302703
PubMed Central: PMC7194583
Links to Exploration step
pubmed:32302703Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.</title>
<author><name sortKey="Roden, Dan M" sort="Roden, Dan M" uniqKey="Roden D" first="Dan M" last="Roden">Dan M. Roden</name>
<affiliation><nlm:affiliation>Interim Division Chief, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine. Electronic address: dan.roden@vumc.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Harrington, Robert A" sort="Harrington, Robert A" uniqKey="Harrington R" first="Robert A" last="Harrington">Robert A. Harrington</name>
<affiliation><nlm:affiliation>President of the American Heart Association.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Poppas, Athena" sort="Poppas, Athena" uniqKey="Poppas A" first="Athena" last="Poppas">Athena Poppas</name>
<affiliation><nlm:affiliation>President of the American College of Cardiology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Russo, Andrea M" sort="Russo, Andrea M" uniqKey="Russo A" first="Andrea M" last="Russo">Andrea M. Russo</name>
<affiliation><nlm:affiliation>President of the Heart Rhythm Society.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32302703</idno>
<idno type="pmid">32302703</idno>
<idno type="doi">10.1016/j.hrthm.2020.04.016</idno>
<idno type="pmc">PMC7194583</idno>
<idno type="wicri:Area/Main/Corpus">001956</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001956</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.</title>
<author><name sortKey="Roden, Dan M" sort="Roden, Dan M" uniqKey="Roden D" first="Dan M" last="Roden">Dan M. Roden</name>
<affiliation><nlm:affiliation>Interim Division Chief, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine. Electronic address: dan.roden@vumc.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Harrington, Robert A" sort="Harrington, Robert A" uniqKey="Harrington R" first="Robert A" last="Harrington">Robert A. Harrington</name>
<affiliation><nlm:affiliation>President of the American Heart Association.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Poppas, Athena" sort="Poppas, Athena" uniqKey="Poppas A" first="Athena" last="Poppas">Athena Poppas</name>
<affiliation><nlm:affiliation>President of the American College of Cardiology.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Russo, Andrea M" sort="Russo, Andrea M" uniqKey="Russo A" first="Andrea M" last="Russo">Andrea M. Russo</name>
<affiliation><nlm:affiliation>President of the Heart Rhythm Society.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Heart rhythm</title>
<idno type="eISSN">1556-3871</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (administration & dosage)</term>
<term>Anti-Infective Agents (adverse effects)</term>
<term>Azithromycin (administration & dosage)</term>
<term>Azithromycin (adverse effects)</term>
<term>Betacoronavirus (drug effects)</term>
<term>COVID-19 (MeSH)</term>
<term>Contraindications, Drug (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Interactions (MeSH)</term>
<term>Drug Monitoring (methods)</term>
<term>Drug Therapy, Combination (adverse effects)</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Electrocardiography (methods)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Long QT Syndrome (chemically induced)</term>
<term>Long QT Syndrome (diagnosis)</term>
<term>Long QT Syndrome (prevention & control)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Torsades de Pointes (chemically induced)</term>
<term>Torsades de Pointes (diagnosis)</term>
<term>Torsades de Pointes (prevention & control)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Infective Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Infective Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Long QT Syndrome</term>
<term>Torsades de Pointes</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Long QT Syndrome</term>
<term>Torsades de Pointes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term>
<term>Drug Therapy, Combination</term>
<term>Electrocardiography</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Long QT Syndrome</term>
<term>Torsades de Pointes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Contraindications, Drug</term>
<term>Drug Interactions</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32302703</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3871</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>7</Issue>
<PubDate><Year>2020</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Heart rhythm</Title>
<ISOAbbreviation>Heart Rhythm</ISOAbbreviation>
</Journal>
<ArticleTitle>Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.</ArticleTitle>
<Pagination><MedlinePgn>e231-e232</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1547-5271(20)30347-7</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrthm.2020.04.016</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roden</LastName>
<ForeName>Dan M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>Interim Division Chief, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine. Electronic address: dan.roden@vumc.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harrington</LastName>
<ForeName>Robert A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo><Affiliation>President of the American Heart Association.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poppas</LastName>
<ForeName>Athena</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>President of the American College of Cardiology.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Russo</LastName>
<ForeName>Andrea M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>President of the Heart Rhythm Society.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017065">Practice Guideline</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Heart Rhythm</MedlineTA>
<NlmUniqueID>101200317</NlmUniqueID>
<ISSNLinking>1547-5271</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="Y">Azithromycin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000075203" MajorTopicYN="N">Contraindications, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008133" MajorTopicYN="Y">Long QT Syndrome</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016171" MajorTopicYN="Y">Torsades de Pointes</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32302703</ArticleId>
<ArticleId IdType="pii">S1547-5271(20)30347-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.hrthm.2020.04.016</ArticleId>
<ArticleId IdType="pmc">PMC7194583</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Toxicol (Phila). 2006;44(2):173-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16615675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Cardiol. 2016;2016:4626279</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27478650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interv Card Electrophysiol. 2007 Apr;18(3):243-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17546486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Rheumatol. 2013 Aug;19(5):286-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23872551</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Res Int. 2018 Oct 14;2018:1574806</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30406128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Arrhythm Electrophysiol. 2017 Apr;10(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28408648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Appl Toxicol. 2015 Jul;35(7):799-805</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25348819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pacing Clin Electrophysiol. 2007 Dec;30(12):1579-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18070319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 May 17;366(20):1881-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22591294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2018 Dec 6;13(12):e0208321</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30521586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs Real World Outcomes. 2016 Mar;3(1):99-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27747808</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mayo Clin Proc. 2020 Jun;95(6):1213-1221</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32359771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Emerg Med. 2019 Dec;37(12):2264.e5-2264.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31477360</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Toxicol. 2017 Oct;17(4):434-440</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28213753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pacing Clin Electrophysiol. 2005 Nov;28(11):1221-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16359290</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Rhythm. 2015 Oct;12(10):2186-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26025323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2013 May 2;368(18):1665-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23635046</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001956 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001956 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32302703 |texte= Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32302703" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |